(MONSO) Monsenso AS - Ratings and Ratios
Exchange: CO • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0061277977
MONSO: Apps, Portals, Data Analytics, Messaging Tools, Therapy Software
Monsenso A/S specializes in developing digital health solutions aimed at improving mental health outcomes. The company offers a comprehensive platform that includes patient and carer apps, a clinical web portal, and advanced data analytics tools. The Monsenso app for individuals provides features such as self-assessments, sensor data collection from mobile devices and wearables, medication and session reminders, motivational feedback, psychoeducation, and secure messaging. The app also includes cognitive behavioral therapy (CBT) tools to support users in managing their mental health effectively.
The carer app is designed to assist caregivers in supporting individuals with mental health conditions. It includes self-assessments, questionnaires, psychoeducation, and learning tools to help carers better understand and address the needs of their loved ones. For clinicians, Monsenso provides a clinical web portal that enables visualization of patient data, historical overviews, correlation analysis, note-keeping, messaging, and shared decision-making. Additionally, the platform offers data analytics capabilities, including historical aggregation of health and behavioral data, statistical descriptors, correlation analysis between behavioral data and illness progression, pattern analysis, predictive analytics, mood forecasting, and risk assessment.
Monsenso A/S serves a diverse range of stakeholders, including patients, clinicians, healthcare systems, researchers, and carers. The company was founded in 2013 and is headquartered in Frederiksberg, Denmark. Monsenso A/S operates in the health care technology sector, focusing on delivering innovative solutions to improve mental health care outcomes.
Technically, MONSO is currently trading below its SMA 20 (0.26) and SMA 50 (0.31), indicating short-term and medium-term weakness. The SMA 200 (0.46) is significantly higher, suggesting a longer-term downtrend. The ATR (0.04) indicates moderate volatility. Given these metrics, the stock is likely to face resistance at the SMA 50 level and could consolidate or decline further in the next three months.
Fundamentally, the company has a market cap of 18.26M DKK, with a P/B ratio of 1.09, indicating that the stock is trading near its book value. The P/S ratio of 1.70 suggests that the market is pricing in moderate growth expectations. However, the negative RoE (-38.50) raises concerns about profitability. The lack of forward P/E suggests that the market is not pricing in significant earnings growth in the near term.
Overall, the technical and fundamental data suggest that MONSO may face headwinds in the next three months, with potential downside risks due to the negative RoE and the stock trading below its key moving averages. Investors should monitor the companys ability to improve profitability and stabilize its technical trend.
Additional Sources for MONSO Stock
MONSO Stock Overview
| Market Cap in USD | 3m |
| Sector | Healthcare |
| Industry | Health Information Services |
| GiC Sub-Industry | Health Care Technology |
| IPO / Inception |
MONSO Stock Ratings
| Growth 5y | -83.1% |
| Fundamental | -31.0% |
| Dividend | 0.0% |
| Rel. Strength Industry | -30.9 |
| Analysts | - |
| Fair Price Momentum | 0.13 DKK |
| Fair Price DCF | - |
MONSO Dividends
No Dividends PaidMONSO Growth Ratios
| Growth Correlation 3m | -86.6% |
| Growth Correlation 12m | -38.9% |
| Growth Correlation 5y | -83.5% |
| CAGR 5y | -51.03% |
| CAGR/Max DD 5y | -0.51 |
| Sharpe Ratio 12m | -0.04 |
| Alpha | -55.69 |
| Beta | 2.60 |
| Volatility | 123.78% |
| Current Volume | 61.6k |
| Average Volume 20d | 42.5k |
As of March 16, 2025, the stock is trading at DKK 0.24 with a total of 61,567 shares traded.
Over the past week, the price has changed by -3.97%, over one month by -6.92%, over three months by -39.50% and over the past year by -30.26%.
Probably not. Based on ValueRay Fundamental Analyses, Monsenso AS (CO:MONSO) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.99 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MONSO as of March 2025 is 0.13. This means that MONSO is currently overvalued and has a potential downside of -45.83%.
Monsenso AS has no consensus analysts rating.
According to ValueRays Forecast Model, MONSO Monsenso AS will be worth about 0.2 in March 2026. The stock is currently trading at 0.24. This means that the stock has a potential downside of -33.33%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.2 | -33.3% |